Parkinson’s disease models and services
Parkinson’s disease (PD) is a brain disorder characterized by progressing movement problems and irreversible damage to the brain
Parkinson’s Disease model options
MPTP Induced PD Models
Seeding Alpha-Synuclein Models
Transgenic Alpha-Synuclein Models
View our comprehensive range of standardized and customized behavioural tests
Brain pathology: alpha-synuclein and substantia nigra degeneration
Key events contributing to the neurodegeneration and clinical symptoms in PD are believed to involve lysosomal dysfunction, the spreading of α-syn aggregates, and neuroinflammation. Various mouse models of PD have been developed to replicate these disease mechanisms effectively.
Tyrosine hydroxylase staining can be used to assess dopaminergic cell loss after localized lesions in the substantia nigra.
Risk factors: SNCA, LRRK2, GBA
Mouse models that replicate these genetic risk factors offer valuable insights into PD and serve as attractive models for studying the disease. These models present an opportunity to test potential treatments for Parkinson’s disease and advance our understanding of its underlying mechanisms.
The people behind the models
Jolien Beekens, PhD, Neurology Study Director
With in vitro screening methods available as a suited first step in your development process our team of experts have the experience to optimise your study design process.
Thomas Vogels, PhD, Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know